Trials / Completed
CompletedNCT01753557
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Naïve or Relapsed After Previous Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-424 | MP-424: 750mg every 8 hours (q8h) for 12 weeks |
| DRUG | RBV | RBV: 600 - 1000 mg/day based on body weight for 24 weeks |
| DRUG | PEG-IFN alfa-2a | PEG-IFN alfa-2a: 180mcg/week for 24 weeks |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2012-12-20
- Last updated
- 2026-01-06
- Results posted
- 2016-10-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01753557. Inclusion in this directory is not an endorsement.